Marco Campitelli, MD
Pulmonary Disease · Watertown, NYNPI 1053790477
Payments from drug & device makers
Across 32 payments — averaging $71.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$1K
- Johnson & Johnson$1K
- Fujifilm Healthcare Americas Corporation$49
- AbbVie$47
- Insmed, Inc.$46
- Inspire Medical Systems, Inc.$23
- plus $57 from 3 others
What the payments were for
- Travel & lodging$1,68374%
- Food & beverage$57125%
- Education$321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 6 | $1,052 |
| Johnson & Johnson(2 entities) | 14 | $1,013 |
| Fujifilm Healthcare Americas Corporation | 2 | $49 |
| AbbVie | 3 | $47 |
| Insmed, Inc. | 3 | $46 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Grifols USA, LLC | 1 | $20 |
| Galvanize Therapeutics, Inc | 1 | $18 |
| Electromed, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$681
- XARELTO$125
How this compares
$2,287 in reported general payments places this provider in the 60th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 153 | $116,874 |
| Pirfenidone | 12 | $83,684 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 123 | $70,894 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 99 | $59,637 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 59 | $42,889 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 38 | $25,329 |
| Breo ElliptaFluticasone/Vilanterol | 50 | $24,528 |
| EliquisApixaban | 30 | $21,361 |
| Varenicline Tartrate | 92 | $17,909 |
| Spiriva RespimatTiotropium Bromide | 27 | $16,526 |
| XolairOmalizumab | 12 | $16,054 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $10,593 |
| SymbicortBudesonide/Formoterol Fumarate | 44 | $10,379 |
| Spiriva HandihalerTiotropium Bromide | 15 | $9,479 |
| Tiotropium Bromide | 15 | $8,817 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Watertown
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.